alendronate has been researched along with Renal Insufficiency, Chronic in 13 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acidosis was induced for 14 days and alendronate was administered every 3 days for the acidosis+BPP group." | 5.91 | Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice. ( Deymier, A; Moody, M; Schmidt, TA; Trivedi, R, 2023) |
| "A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD." | 5.22 | Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. ( Abrahamsen, B; Arden, N; Calderon-Larranaga, S; Cooper, C; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Prieto-Alhambra, D; Sami, A; Van Staa, TP, 2022) |
| " In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD." | 3.85 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2017) |
| " Incidences of adverse events, asymptomatic decreases in serum calcium, and evolution of kidney function during the studies were similar across all baseline kidney function groups." | 3.11 | Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. ( Adachi, JD; Albergaria, BH; Cheung, AM; Chines, AA; Gielen, E; Langdahl, BL; Miller, PD; Miyauchi, A; Oates, M; Reid, IR; Santiago, NR; Vanderkelen, M; Wang, Z; Yu, Z, 2022) |
| " We calculated the standard mean deviations with 95% confidence intervals (CI) for bone mineral density (BMD) and T scores after 6 and 12 months treatment, pooled odds ratio and 95% CI for fracture risk, and summarized adverse events." | 3.01 | Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. ( Leng, Y; Xia, Y; Yang, Y; Yu, X, 2023) |
| "Acidosis was induced for 14 days and alendronate was administered every 3 days for the acidosis+BPP group." | 1.91 | Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice. ( Deymier, A; Moody, M; Schmidt, TA; Trivedi, R, 2023) |
| "Alendronate non-users were identified using incidence density sampling and matched groups were created using propensity scores." | 1.56 | Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark. ( Ali, MS; Arden, NK; Ben-Shlomo, Y; Caskey, F; Cooper, C; Ernst, M; Hermann, AP; Javaid, MK; Judge, A; Nybo, M; Prieto-Alhambra, D; Robinson, DE; Rubin, KH, 2020) |
| "The efficacy and renal safety of low-dose/high-frequency (LDHF) dosing and high-dose/low-frequency (HDLF) dosing of bisphosphonates (BPs) are comparable in patients with normal kidney function but might be different in patients with late-stage chronic kidney disease (CKD)." | 1.56 | Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model. ( Fujita, R; Iwasaki, N; Kimura-Suda, H; Kobayashi, H; Nakamura, F; Nakazawa, D; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2020) |
| "To review the product information (PI) for various brands of the same generic drugs and investigate the extent to which information is currently available on dosing in renal impairment and the concordance between the dosing recommendations for the same generic drug." | 1.40 | Renal drug dosing recommendations: evaluation of product information for brands of the same drug. ( Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Khalid, S | 1 |
| Calderon-Larranaga, S | 1 |
| Sami, A | 1 |
| Hawley, S | 1 |
| Judge, A | 2 |
| Arden, N | 1 |
| Van Staa, TP | 1 |
| Cooper, C | 2 |
| Abrahamsen, B | 1 |
| Javaid, MK | 2 |
| Prieto-Alhambra, D | 2 |
| Miller, PD | 1 |
| Adachi, JD | 1 |
| Albergaria, BH | 1 |
| Cheung, AM | 1 |
| Chines, AA | 1 |
| Gielen, E | 1 |
| Langdahl, BL | 1 |
| Miyauchi, A | 1 |
| Oates, M | 1 |
| Reid, IR | 1 |
| Santiago, NR | 1 |
| Vanderkelen, M | 1 |
| Wang, Z | 1 |
| Yu, Z | 1 |
| Leng, Y | 1 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Xia, Y | 1 |
| Moody, M | 1 |
| Schmidt, TA | 1 |
| Trivedi, R | 1 |
| Deymier, A | 1 |
| Harata, S | 1 |
| Kasukawa, Y | 1 |
| Nozaka, K | 1 |
| Tsuchie, H | 1 |
| Shoji, R | 1 |
| Igarashi, S | 1 |
| Kasama, F | 1 |
| Oya, K | 1 |
| Okamoto, K | 1 |
| Miyakoshi, N | 1 |
| Ali, MS | 1 |
| Ernst, M | 1 |
| Robinson, DE | 1 |
| Caskey, F | 1 |
| Arden, NK | 1 |
| Ben-Shlomo, Y | 1 |
| Nybo, M | 1 |
| Rubin, KH | 1 |
| Hermann, AP | 1 |
| Fujita, R | 1 |
| Ota, M | 2 |
| Sato, D | 2 |
| Nakazawa, D | 1 |
| Kimura-Suda, H | 2 |
| Nakamura, F | 1 |
| Shimizu, T | 2 |
| Kobayashi, H | 1 |
| Iwasaki, N | 2 |
| Takahata, M | 2 |
| Hildebrand, S | 1 |
| Cunningham, J | 1 |
| Aggarwal, HK | 1 |
| Jain, D | 1 |
| Chhabra, P | 1 |
| Yadav, RK | 1 |
| Khanal, A | 1 |
| Peterson, GM | 1 |
| Castelino, RL | 1 |
| Jose, MD | 1 |
| Kanehira, Y | 1 |
| Kameda, Y | 1 |
| Hamano, H | 1 |
| Hiratsuka, S | 1 |
| Rosen, H | 1 |
| Yamamoto, S | 1 |
| Suzuki, A | 1 |
| Sasaki, H | 1 |
| Sekiguchi-Ueda, S | 1 |
| Asano, S | 1 |
| Shibata, M | 1 |
| Hayakawa, N | 1 |
| Hashimoto, S | 1 |
| Hoshinaga, K | 1 |
| Itoh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis[NCT01575834] | Phase 3 | 7,180 participants (Actual) | Interventional | 2012-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 13.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 5.5 |
| Romosozumab/Denosumab | 16.6 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 5.5 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 2.3 |
| Romosozumab/Denosumab | 7.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 3.2 |
| Romosozumab/Denosumab | 8.5 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.5 |
| Romosozumab | 1.6 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 4.1 |
| Romosozumab/Denosumab | 2.8 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 0.2 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.6 |
| Romosozumab/Denosumab | 0.3 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.5 |
| Romosozumab | 1.0 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.8 |
| Romosozumab/Denosumab | 1.9 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 1.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.1 |
| Romosozumab/Denosumab | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.1 |
| Romosozumab | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.6 |
| Romosozumab/Denosumab | 2.7 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 0.03 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.5 |
| Romosozumab/Denosumab | 0.03 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.6 |
2 reviews available for alendronate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Diabetes Mellitus | 2022 |
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; | 2023 |
3 trials available for alendronate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Femur N | 2022 |
Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship | 2018 |
Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.
Topics: Adult; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Remodeling; Collage | 2013 |
8 other studies available for alendronate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice.
Topics: Acidosis; Alendronate; Ammonium Chloride; Animals; Diphosphonates; Mice; Osteolysis; Renal Insuffici | 2023 |
Effects of bisphosphonates and treadmill exercise on bone and kidney in adenine-induced chronic kidney disease rats.
Topics: Aged; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fibrosis | 2023 |
Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denmark; Female; Humans; Propensity Sco | 2020 |
Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Humans; Kidne | 2020 |
Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?
Topics: Alendronate; Diphosphonates; Female; Humans; Ibandronic Acid; Renal Insufficiency, Chronic; Vascular | 2021 |
Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Topics: Administration, Oral; Alendronate; Cardiovascular Agents; Central Nervous System Agents; Contraindic | 2014 |
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2017 |
Review of comparative effectiveness of treatments to prevent fractures.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis; Renal Insuffic | 2008 |